Beyond COVID and cancer: In which indications will we see mRNA technology succeed next? And what technological advances might next-generation mRNA platforms offer over those used in the COVID-19 vaccines?
As the COVID-19 pandemic rages on, the effects of the virus are being felt not only by the global populace, but by the various sectors of the health care industry and those that support them.
In this post, we continue our report on some of the precision medicine approaches and initiatives we noted at ASCO. Neoantigens Revitalizing Cancer Vaccine Efforts Early efforts to create cancer vaccines aimed at increasing the immune system’s exposure to tumors, but the effectiveness of first-generation vaccines created by Dendreon and others was limited....
Glioblastoma multiforme (GBM) is the most common form of brain cancer affecting adults. It is also one of the deadliest and hardest to treat cancers. About half of all people with GBM survive longer than 18 months, but only 15% are still alive five years post diagnosis. Of the approximately two dozen experimental treatments tested...